FERRARI, Roberto
 Distribuzione geografica
Continente #
NA - Nord America 36.802
EU - Europa 9.990
AS - Asia 5.002
SA - Sud America 75
OC - Oceania 25
AF - Africa 20
Continente sconosciuto - Info sul continente non disponibili 14
Totale 51.928
Nazione #
US - Stati Uniti d'America 36.743
CN - Cina 3.219
IT - Italia 2.713
UA - Ucraina 2.390
TR - Turchia 1.425
DE - Germania 1.278
GB - Regno Unito 999
SE - Svezia 697
FI - Finlandia 519
PL - Polonia 483
BE - Belgio 421
FR - Francia 212
VN - Vietnam 125
IN - India 52
CA - Canada 39
ES - Italia 36
RU - Federazione Russa 36
BR - Brasile 31
HK - Hong Kong 29
CH - Svizzera 25
NL - Olanda 25
IE - Irlanda 21
KR - Corea 21
AU - Australia 18
CZ - Repubblica Ceca 18
CO - Colombia 16
LK - Sri Lanka 16
RO - Romania 15
EU - Europa 12
HR - Croazia 12
MX - Messico 12
IR - Iran 11
SG - Singapore 11
AL - Albania 10
PT - Portogallo 10
ID - Indonesia 9
PK - Pakistan 9
TW - Taiwan 9
EC - Ecuador 8
GE - Georgia 8
HU - Ungheria 8
IL - Israele 8
JP - Giappone 8
RS - Serbia 8
CL - Cile 7
DK - Danimarca 7
GR - Grecia 7
NZ - Nuova Zelanda 7
TH - Thailandia 7
AR - Argentina 6
EG - Egitto 6
IQ - Iraq 6
LT - Lituania 6
NO - Norvegia 6
BG - Bulgaria 5
MY - Malesia 5
PH - Filippine 5
ZA - Sudafrica 5
AT - Austria 4
MK - Macedonia 4
SI - Slovenia 4
SK - Slovacchia (Repubblica Slovacca) 4
BO - Bolivia 3
CU - Cuba 3
MD - Moldavia 3
PE - Perù 3
SA - Arabia Saudita 3
AM - Armenia 2
CY - Cipro 2
ET - Etiopia 2
KW - Kuwait 2
MA - Marocco 2
NI - Nicaragua 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AF - Afghanistan, Repubblica islamica di 1
AP - ???statistics.table.value.countryCode.AP??? 1
BD - Bangladesh 1
BH - Bahrain 1
BN - Brunei Darussalam 1
EE - Estonia 1
GL - Groenlandia 1
HN - Honduras 1
KE - Kenya 1
KZ - Kazakistan 1
LB - Libano 1
LI - Liechtenstein 1
LU - Lussemburgo 1
MM - Myanmar 1
NP - Nepal 1
PA - Panama 1
PY - Paraguay 1
RE - Reunion 1
SM - San Marino 1
SY - Repubblica araba siriana 1
TZ - Tanzania 1
Totale 51.928
Città #
Fairfield 5.337
Woodbridge 5.000
Houston 3.146
Jacksonville 2.703
Ashburn 2.591
Chandler 2.389
Ann Arbor 2.106
Seattle 2.087
Wilmington 1.864
Cambridge 1.776
Izmir 946
Nanjing 866
Princeton 751
Beijing 558
San Diego 474
Warsaw 471
Brussels 419
Boardman 391
Ferrara 298
Milan 283
Shenyang 258
Nanchang 244
New York 227
Shanghai 172
Falls Church 155
Hebei 147
Changsha 143
Jiaxing 143
Bremen 134
Redwood City 132
Tianjin 129
San Mateo 121
Mountain View 119
Dong Ket 118
London 114
Addison 107
Jinan 96
Rome 94
Norwalk 82
Zhengzhou 81
Dearborn 80
Ningbo 64
Kunming 62
Philadelphia 62
Washington 56
Des Moines 53
Orange 51
Verona 48
Taizhou 45
Napoli 43
Guangzhou 39
Indiana 38
Naples 38
Bologna 36
Chicago 35
Tappahannock 35
Helsinki 33
Auburn Hills 28
Redmond 27
Hangzhou 26
Changchun 24
Hong Kong 23
Kilburn 23
Los Angeles 23
Lanzhou 22
Padova 22
Hounslow 20
Augusta 18
Bari 17
Leawood 17
Turin 17
Florence 16
Torino 16
Palermo 15
Genova 14
San Francisco 14
Yellow Springs 12
Haikou 11
Hefei 11
Monmouth Junction 11
Munich 11
Brno 10
Dublin 10
Hamburg 10
Montréal 10
Pisa 10
Braunschweig 9
Catania 9
Chiswick 9
Mumbai 9
New Bedfont 9
Cagliari 8
Paris 8
Saronno 8
Tbilisi 8
Zagreb 8
Brescia 7
Carrara 7
Caserta 7
Como 7
Totale 38.691
Nome #
IL METABOLISMO DEL MIOCARDIO ISCHEMICO IBERNATO E STORDITO: DIFFERENZA TRA NECROSI E APOPTOSI 1.605
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD 256
Physical activity intervention for elderly patients with reduced physical performance after acute coronary syndrome (HULK study): Rationale and design of a randomized clinical trial 250
null 206
Il lungo cammino degli inibitori dell'enzima di conversione dell'angiotensina nella lotta per le malattie cardiovascolari 191
Scompenso cardiaco con frazione di eiezione intermedia. Alla ricerca della Terra di Mezzo? 188
Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease 187
Distinct gene expression profiles associated with Notch ligands Delta-like 4 and Jagged1 in plaque material from peripheral artery disease patients: A pilot study 185
Valutazione ecocardiografica dell'insufficienza mitralica nella prospettiva della riparazione valvolare 180
The Notch pathway: a novel therapeutic target for cardiovascular diseases? 180
Estrogen receptor β-dependent Notch1 activation protects vascular endothelium against tumor necrosis factor α (TNFα)-induced apoptosis 178
Left ventricular ejection fraction and heart failure: an indissoluble marriage? 171
Demographic and clinical characteristics of patients with stable coronary artery disease: results from the CLARIFY registry in Spain 164
Fo ATP synthase C subunit serum levels in patients with ST-segment Elevation Myocardial Infarction: Preliminary findings 157
Effects of temperature on myocardial calcium homeostasis and mitochondrial function during ischemia and reperfusion. 155
Mitochondrial permeability transition involves dissociation of F1FO ATP synthase dimers and C-ring conformation 155
Polar plot maps by parametric strain echocardiography allow accurate evaluation of non-viable transmural scar tissue in ischaemic heart disease 152
New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma 150
17β-Estradiol Enhances Signalling Mediated by VEGF-A-Delta-Like Ligand 4-Notch1 Axis in Human Endothelial Cells 148
Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile 146
Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL 145
Reversibility of Left Ventricle Longitudinal Strain Alterations Induced by Adjuvant Therapy in Early Breast Cancer Patients 145
Heart failure with preserved ejection fraction: uncertainties and dilemmas 144
Cardiac resynchronization therapy guided by multimodality cardiac imaging 143
Kounis-Zavras syndrome presenting with ventricular arrhythmias and cardiogenic shock 140
Factor XI rs2036914 gene polymorphism and occurrence of adverse events after percutaneous coronary intervention. A prospective evaluation. 140
CANCER THERAPY-INDUCED CARDIOTOXICITY: ROLE OF ULTRASOUND DEFORMATION IMAGING AS AN AID TO EARLY DIAGNOSIS 140
The role of Notch pathway in cardiovascular diseases. 140
Tissue factor and coagulation factor VII levels during acute myocardial infarction: association with genotype and adverse events. 138
The frailty in elderly patients receiving cardiac interventional procedures (FRASER) program: rational and design of a multicenter prospective study 138
2013 ESC guidelines on the management of stable coronary artery disease 137
The role of notch in the cardiovascular system: potential adverse effects of investigational notch inhibitors 137
1,3,8-Triazaspiro compounds and their use as medicaments for the treatment of reperfusion injury. 133
Uric acid and coronary artery disease: An elusive link deserving further attention 132
Inhaled corticosteroid/long-acting bronchodilator treatment mitigates STEMI clinical presentation in COPD patients 131
Discovery of Novel 1,3,8-Triazaspiro[4.5]decane Derivatives That Target the c Subunit of F1/FO-Adenosine Triphosphate (ATP) Synthase for the Treatment of Reperfusion Damage in Myocardial Infarction 129
Poor response to clopidogrel: current and future options for its management 129
Prolonged propionyl-L-carnitine pre-treatment of rabbit: biochemical, hemodynamic and electrophysiological effects on myocardium. 128
Predischarge screening for chronic obstructive pulmonary disease in patients with acute coronary syndrome and smoking history 128
Medical and interventional management of patients with severe thrombocytopenia undergoing percutaneous coronary intervention 127
Fractional flow reserve evaluation and chronic kidney disease: Analysis from a multicenter Italian registry (the FREAK study) 126
Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: Systematic review and meta-analysis 126
Individualized angiotensin-converting enzyme (ACE)-inhibitor therapy in stable coronary artery disease based on clinical and pharmacogenetic determinants: The PERindopril GENEtic (PERGENE) risk model 125
Short Physical Performance Battery and all-cause mortality: Systematic review and meta-analysis 125
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy 124
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) 124
2014 ESC guidelines on the diagnosis and treatment of aortic diseases 124
Management of coronary artery disease patients in Latvia compared with practice in Central-Eastern Europe and globally: Analysis of the CLARIFY registry 124
EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT) 124
Coronary artery disease: Use of ACE inhibitors in stable CAD - What is the truth? 123
Reperfusion Damage - A Story of Success, Failure, and Hope 123
Tailored Medical and Interventional Therapy Against Recurrent Stent Thrombosis After Drug-Eluting Stenting 122
European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions 122
Ticagrelor improves endothelial function by decreasing circulating Epidermal Growth Factor (EGF) 122
Cardiovascular complications of radiation therapy for thoracic malignancies: The role for non-invasive imaging for detection of cardiovascular disease 121
KRIT1 deficiency promotes aortic endothelial dysfunction 121
Can we improve myocardial protection during ischaemic injury? 120
Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study 119
The in vitro effects of verbascoside on human platelet aggregation 118
Randomized, double-blind comparison of effects of abiciximab bolus only vs. on-label regimen on ex vivo inhibition of platelet aggregation in responders to clopidogrel undergoing coronary stenting 118
In Vitro Characterization of Circulating Endothelial Progenitor Cells Isolated from Patients with Acute Coronary Syndrome 118
Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention 118
A counseling program on nuisance bleeding improves quality of life in patients on dual antiplatelet therapy: A randomized controlled trial 117
CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure 117
Factor XIII-A dynamics in acute myocardial infarction: a novel prognostic biomarker? 117
Not just numbers, but years of science: Putting the ACE inhibitor—ARB meta-analyses into context 116
Clinical benefit of drugs targeting mitochondrial function as an adjunct to reperfusion in ST-segment elevation myocardial infarction: A meta-analysis of randomized clinical trials 116
RESTING HEART RATE IN CARDIOVASCULAR DISEASE 115
Antiplatelet Treatment Reduces All-Cause Mortality in COPD Patients: A Systematic Review and Meta-Analysis 115
Grip strength predicts cardiac adverse events in patients with cardiac disorders: An individual patient pooled meta-analysis 115
ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes 114
Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease - Results from EUROPA 114
Time course of human atrial natriuretic factor release during cardiopulmonary bypass in mitral valve and coronary artery diseased patients. 113
Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis 113
Sex-specific benefits of sirolimus-eluting stent on long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study trial 113
A Strategy to offset the extra cost of sirolimus-eluting stent in patients undergoing intervention for acute myocardial infarction. 112
Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: A randomized multicenter trial 112
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials 112
EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot) 112
Angiotensin-converting enzyme inhibition in cardiovascular disease evidence with perindopril 111
Abnormalities of left ventricular function in asymptomatic patients with systemic sclerosis using doppler measures of myocardial strain. 111
The assessment of scales of frailty and physical performance improves prediction of major adverse cardiac events in older adults with acute coronary syndrome 111
Long-Term Effect of Perindopril on Coronary Atherosclerosis Progression (from the PERindopril's Prospective Effect on Coronary aTherosclerosis by Angiography and IntraVascular Ultrasound Evaluation [PERSPECTIVE] Study) 110
Is stunning an important component of preconditioning? 110
ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes (Am Journal of Cardiovasc Drugs (2011) 11:3 (189-98)) 110
International cooperation in healthcare: Model of IRCCS Policlinico San Donato and Bambini Cardiopatici nel Mondo Association for congenital heart diseases 110
Reduction of oxidative stress by carvedilol: role in maintenance of ischaemic myocardium viability. 109
Radiofrequency ablation of atrial fibrillation: is the persistence of all intraprocedural targets necessary for long-term maintenance of sinus rhythm? 109
Impact of a recent hospitalization on treatment and prognosis of ST-segment elevation myocardial infarction 109
2013 ESCGuidelines on cardiac pacing and cardiac resynchronization therapy 109
Long-term treatment with ivabradine in post-myocardial infarcted rats counteracts f-channel overexpression 109
Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: Systematic review and meta-analysis 109
Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: An analysis from the SIGNIFY study 109
Endothelial dysfunction in acute and chronic coronary syndromes: evidence for a pathogenetic role of oxidative stress 109
A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals 109
Current views on anthracycline cardiotoxicity 109
null 108
The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease 108
Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke) 108
181 QUESTIONS & ANSWERS IN HEART FAILURE Heart failure 181 Questions & Answers. 108
Totale 14.653
Categoria #
all - tutte 178.539
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 3.240
Totale 181.779


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20196.512 0 0 0 0 0 0 0 0 619 1.297 1.740 2.856
2019/202012.211 1.880 441 464 1.743 857 1.426 1.121 1.276 1.024 1.199 488 292
2020/20218.376 681 744 515 930 363 913 316 1.061 254 1.119 996 484
2021/20227.070 323 777 577 273 413 357 359 366 296 505 753 2.071
2022/20236.287 715 190 226 668 982 900 252 678 846 77 501 252
2023/20242.428 376 534 230 140 293 490 152 206 7 0 0 0
Totale 52.890